 BOULDER, Colo.--BUSINESS WIRE--Edgewise Therapeutics, Inc., NASDAQ: EWTX, a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, today reported financial results for the first quarter 2021 and recent business highlights. Our successful IPO was transformative for Edgewise, providing the financial stability to advance a meaningful pipeline of novel therapeutics for severe, rare muscle disorders, said Kevin Ko 